Search For "sun pharmaceutical"
Lilly signs pacts with Cipla, Lupin, Sun Pharma to accelerate availability
Updated : 4 years, 10 months ago IST
New Delhi [India], May 10 (ANI): US pharmaceutical major Eli Lilly said on Monday it has issued royalty-free, non-exclusive voluntary licenses to Cipla, Lupin and Sun Pharmaceutical to accelerate and expand the availability of baricitinib in India for Covid-19 patients.
Read More
Lupin launches Favipiravir in India for COVID treatment at Rs 49 per table
Updated : 5 years, 7 months ago IST
Mumbai (Maharashtra) [India], Aug 5 (ANI): Pharma major Lupin Ltd on Wednesday announced the launch of Favipiravir in India under the brand name Covihalt for treatment of mild to moderate COVID-19.
Read More
Sun Pharma launches Favipiravir in India for Rs 35 per tablet
Updated : 5 years, 7 months ago IST
Mumbai (Maharashtra) [India], Aug 4 (ANI): Sun Pharmaceutical Industries said on Tuesday it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19.
Read More
Sun Pharma's arm Taro achieves global resolution of US DoJ anti-trust prob
Updated : 5 years, 8 months ago IST
Mumbai (Maharashtra) [India], July 24 (ANI): Sun Pharmaceutical Industries said on Friday its US-based subsidiary Taro Pharmaceutical Inc has resolved all cases in connection with multi-year investigations by the Department of Justice's (DoJ's) Anti-trust Division and Civil Division into the
Read More
Sun Pharma initiates phase two clinical trial on AQCH as potential treatme
Updated : 5 years, 9 months ago IST
Mumbai (Maharashtra) [India], June 5 (ANI): Sun Pharmaceutical Industries has started phase two clinical trial on AQCH, a phytopharmaceutical (plant-derived) drug for the treatment of COVID-19.
Read More
Sun Pharma gets DCGI approval for clinical trial with Nafamostat in Covid-
Updated : 5 years, 10 months ago IST
Mumbai (Maharashtra) [India], May 29 (ANI): Sun Pharmaceutical Industries said on Friday it has received approval from the Drugs Controller General of India (DCGI) to initiate clinical trial with Nafamostat Mesilate in Covid-19 patients.
Read More
Sun Pharma's Q2 net profit up 12.6 pc at Rs 1,064 crore
Updated : 6 years, 4 months ago IST
Mumbai (Maharashtra) [India], Nov 7 (ANI): Sun Pharmaceutical Industries on Thursday reported a consolidated net profit for the second fiscal quarter at Rs 1,064 crore with resulting net profit margin at 13.4 per cent.
Read More
Sun Pharma, AstraZeneca enter into license pact for novel oncology product
Updated : 6 years, 4 months ago IST
Mumbai (Maharashtra) [India], Nov 6 (ANI): Sun Pharmaceutical Industries said on Wednesday it has entered into a licensing agreement with AstraZeneca UK Ltd to introduce certain novel ready-to-use infusion oncology products in China.
Read More
Equity indices end volatile session higher, Sun Pharma and Maruti Suzuki t
Updated : 6 years, 6 months ago IST
Mumbai (Maharashtra) [India], Sept 4 (ANI): Equity benchmark indices witnessed an extremely volatile session on Wednesday but managed to end positive.
Read More
Sun Pharma signs licensing pact with CSIR-IICT
Updated : 6 years, 7 months ago IST
Mumbai (Maharashtra) [India], Aug 14 (ANI): Sun Pharmaceutical Industries said on Wednesday that it has entered into a global licensing agreement with the CSIR Indian Institute of Chemical Technology (CSIR-IICT) in Hyderabad for patents related to certain compounds.
Read More
Sun Pharma reports 31 pc jump in Q1 net profit at Rs 1,387 crore
Updated : 6 years, 7 months ago IST
Mumbai (Maharashtra) [India], Aug 13 (ANI): Sun Pharmaceutical on Tuesday reported a net profit of Rs 1,387 crore in the April to June quarter of 2019-20, up 31 per cent in the year-on period.
Read More
Sun Pharma reports 49% jump in net profit at Rs 1,242 crore during Q3
Updated : 7 years, 1 month ago IST
Mumbai (Maharashtra) [India], Feb 13 (ANI): Sun Pharmaceutical Industries has registered gross sales of Rs 7,657 crore in the quarter ending December 2018, marking 16 per cent growth over the same quarter in previous year.
Read More